Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX

Completed · Phase 2

Conditions studied: Colorectal Cancer, Nausea and Vomiting

In brief

RATIONALE: Aprepitant, palonosetron, and dexamethasone may help lessen or prevent nausea and vomiting in patients receiving chemotherapy. PURPOSE: This phase II trial is studying how well giving aprepitant together with palonosetron and dexamethasone works in preventing nausea and vomiting caused by chemotherapy in patients receiving chemotherapy for metastatic colorectal cancer.

Key facts

Study ID

NCT00381862

Run by

OHSU Knight Cancer Institute

People needed

54

Starts

2006-06-01

Expected to finish

2008-07-01

Last updated by the study team

2017-06-12

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• St. Josephs/Cander Hospital — Savannah, Georgia, United States
• Kaiser Permanente — Hilo, Hawaii, United States
• Ingalls Memorial Hospital — Harvey, Illinois, United States
• Kansas City Cancer Center — Kansas City, Missouri, United States
• OHSU Knight Cancer Institute — Portland, Oregon, United States
• Texas A & M university / Scott and White Clinic — Temple, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.